在系统性自身免疫性疾病中通过循环免疫复合体激活Fcγ受体,并通过CD19-CAR T细胞疗法降低其活性

Merle Freitag1, Philipp Kolb2,3, Valeria Falcone2,3

  • 1Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

PubMed
概括

循环免疫复合体 (cIC) 在结合组织疾病 (CTD) 中具有生物活性,激活Fcγ受体. 它们的生物活性与疾病呈现相关,并在CTD患者的CD19-CAR T细胞治疗后得到改善.

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457